Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo Comparando Zanubrutinibe + Rituximabe Versus Bendamustina + Rituximabe em Participantes com Linfoma de Células do Manto Não Tratado (MANGROVE)

25 de setembro de 2026 atualizado por: BeOne Medicines

Um estudo randomizado, aberto e multicêntrico de Fase 3 comparando Zanubrutinibe (BGB-3111) mais Rituximabe versus Bendamustina mais Rituximabe em pacientes com linfoma de células do manto não tratados anteriormente que não são elegíveis para transplante de células-tronco

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Tipo de estudo

Intervencional

Inscrição (Real)

510

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Cologne, Alemanha, 50937
        • Uniklinik Koln (Aor)
      • Heidelberg, Alemanha, 69120
        • Universitatsklinikum Heidelberg
      • Munich, Alemanha, 81377
        • Dept of Medicine Iii, University Hospitallmu
      • Ulm, Alemanha, 89081
        • Universitaetsklinikum Ulm, Innere Medizin Iii
      • Wuppertal, Alemanha, 42283
        • Petrus Krankenhaus Wuppertal
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Austrália, 2605
        • Canberra Hospital
    • New South Wales
      • Concord, New South Wales, Austrália, 2139
        • Concord Repatriation General Hospital
      • Cudgen, New South Wales, Austrália, 2487
        • The Tweed Valley Hospital
      • Darlinghurst, New South Wales, Austrália, 2010
        • Saint Vincents Hospital Sydney
      • Gosford, New South Wales, Austrália, 2250
        • Gosford Hospital
      • Waratah, New South Wales, Austrália, 2298
        • Calvary Mater Newcastle
    • Queensland
      • Birtinya, Queensland, Austrália, 4575
        • Sunshine Coast Hospital and Health Service
      • South Brisbane, Queensland, Austrália, 4101
        • Icon Cancer Foundation
    • South Australia
      • Bedford PK, South Australia, Austrália, 5042
        • Flinders Medical Centre
    • Tasmania
      • Hobart, Tasmania, Austrália, 7000
        • Royal Hobart Hospital
    • Victoria
      • Clayton, Victoria, Austrália, 3168
        • Monash Health
      • Fitzroy, Victoria, Austrália, 3065
        • St Vincents Hospital Melbourne
      • Frankston, Victoria, Austrália, 3199
        • Peninsula Private Hospital
      • Geelong, Victoria, Austrália, 3220
        • Barwon Health the Geelong Hospital
    • Western Australia
      • Perth, Western Australia, Austrália, 6000
        • Royal Perth Hospital
      • Bruges, Bélgica, 8000
        • Az Sint Jan Brugge
      • Brussels, Bélgica, 1090
        • Universitair Ziekenhuis Brussel
      • Edegem, Bélgica, 2650
        • Uz Antwerpen
      • Kortrijk, Bélgica, 8500
        • Az Groeninge Campus Loofstraat
      • Liège, Bélgica, 4000
        • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
      • Yvoir, Bélgica, 5530
        • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
    • Ontario
      • Ottawa, Ontario, Canadá, K1H 8M2
        • The Ottawa Hospital
    • Quebec
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Ciusss de Lestrie Chus
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100044
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, China, 100050
        • Beijing Friendship Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Fujian Medical University Union Hospital
      • Quanzhou, Fujian, China, 362000
        • Quanzhou First Affliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Guangdong Provincial Peoples Hospital
      • Guangzhou, Guangdong, China, 510515
        • Nanfang Hospital of Southern Medical University
      • Guangzhou, Guangdong, China, 510060
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150000
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, China, 450000
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, China, 410013
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Jiangsu Province Hospital
      • Nanjing, Jiangsu, China, 210008
        • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
      • Xuzhou, Jiangsu, China, 221000
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • The First Affiliated Hospital of Nanchang University Branch Donghu
    • Jilin
      • Changchun, Jilin, China, 130021
        • The First Hospital of Jilin University
      • Changchun, Jilin, China, 130021
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, China, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200000
        • Fudan University Shanghai Cancer Center
      • Shanghai, Shanghai Municipality, China, 200120
        • Shanghai East Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • West China Hospital, Sichuan University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin, Tianjin Municipality, China, 300020
        • Institute of Hematology and Hospital of Blood Disease
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830000
        • Affiliated Cancer Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, China, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, China, 315000
        • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
      • Barcelona, Espanha, 08035
        • Hospital Universitario Vall Dhebron
      • Barcelona, Espanha, 08916
        • Ico Hug Trias I Pujol
      • Barcelona, Espanha, 08908
        • Institut Catala Doncologia
      • Girona, Espanha, 17007
        • Ico Girona
      • Madrid, Espanha, 28046
        • Hospital Universitario La Paz
      • Madrid, Espanha, 28040
        • Start Madrid Fundacion Jimenez Diaz
      • Madrid, Espanha, 28033
        • Md Anderson Cancer Center Madrid Spain
      • Madrid, Espanha, 28009
        • Hospital Universitario Gregorio Maranon
      • Málaga, Espanha, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, Espanha, 41013
        • Hospital Universitario Virgen Del Rocio
    • California
      • Orange, California, Estados Unidos, 92868
        • Chao Family Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215-5400
        • Beth Israel Deaconess Medical Center (Bidmc)
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Health System
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine At Mount Sinai
      • Westbury, New York, Estados Unidos, 11590
        • Clinical Research Alliance, Inc
    • Oregon
      • Portland, Oregon, Estados Unidos, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • West Penn Hospital
    • Texas
      • Houston, Texas, Estados Unidos, 77030-4009
        • The University of Texas Md Anderson Cancer Center
      • Lubbock, Texas, Estados Unidos, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Seattle Cancer Care Alliance
      • Bordeaux, França, 33076
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • Brest, França, 29200
        • Chru de Brest Hospital Morvan
      • Dijon, França, J4V 2H1
        • Chu Dijon
      • Grenoble, França, 38043
        • Chu Grenoble Alpes
      • Le Mans, França, 72037
        • Centre Hospitalier Le Mans
      • Lille, França, 59000
        • Hopital Claude Huriez Chu Lille
      • Marseille, França, 13009
        • Institut Paoli Calmettes
      • Nantes, França, 44093
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • Paris, França, 75005
        • Institut Curie
      • Paris, França, 75015
        • Necker University Hospital
      • PierreBenite, França, 69495
        • Chu Hopital Lyon Sud
      • Poitiers, França, 86000
        • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
      • Quimper, França, 29000
        • Ch Cornouaille
      • Toulouse, França, 31059
        • Iuc Toulouse Oncopole
      • Goes, Holanda, 4462 RA
        • Admiraal de Ruijter Ziekenhuis
      • Groningen, Holanda, 9713 GZ
        • University of Medical Center Groningen (Umcg)
      • Nieuwegein, Holanda, 3435 CM
        • St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
      • Nijmegen, Holanda, 6525 GA
        • Albert Schweitzer Ziekenhuis
      • Rotterdam, Holanda, 3015 GD
        • Erasmus Mc
      • The Hague, Holanda, 2545 CH
        • Hagaziekenhuis
      • Cork, Irlanda, t12DC4A
        • Cork University Hospital
      • Dublin, Irlanda, D7
        • Mater Misericordiae University Hospital
      • Dublin, Irlanda, D8
        • St Jamess Hospital
      • Galway, Irlanda, H91 YR71
        • University Hospital Galway
      • Limerick, Irlanda, V94F858
        • University Hospital Limerick
      • Waterford, Irlanda, X91 ER8E
        • University Hospital Waterford
      • Alessandria, Itália, 15121
        • Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
      • Bologna, Itália, 40138
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Genova, Itália, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Milan, Itália, 20162
        • Niguarda Cancer Center Division of Hematology
      • Novara, Itália, 28100
        • Aou Maggiore Della Carita
      • Palermo, Itália, 90146
        • Aoor Villa Sofia Cervello
      • Pisa, Itália, 56126
        • Aou Pisana, Stabilimento Di Santa Chiara
      • Ravenna, Itália, 48121
        • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
      • Reggio Emilia, Itália, 42123
        • Azienda Unita Sanitaria Locale Irccs
      • Roma, Itália, 00161
        • Universita Degli Studi La Sapienza
      • Siena, Itália, 53100
        • Aou Senese Policlinico Santa Maria Alle Scotte
      • Torino, Itália, 10126
        • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
      • Verona, Itália, 37142
        • University of Verona
      • Yokohama, Japão, 221-0855
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 460-0001
        • National Hospital Organization Nagoya Medical Center
      • Toyohashi, Aichi-ken, Japão, 441-8570
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba, Chiba, Japão, 260-8717
        • Chiba Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japão, 830-0011
        • Kurume University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japão, 730-8619
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japão, 241-8515
        • Kanagawa Cancer Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japão, 860-0008
        • National Hospital Organization Kumamoto Medical Center
    • Kyoto
      • Kyoto, Kyoto, Japão, 602-8566
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Japão, 980-8574
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japão, 710-8602
        • Kurashiki Central Hospital
      • Okayama, Okayama-ken, Japão, 701-1192
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka, Osaka, Japão, 545-8586
        • Osaka Metropolitan University Hospital
      • Osakashi, Osaka, Japão, 543-8555
        • Osaka Red Cross Hospital
    • Tokyo
      • Chuoku, Tokyo, Japão, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Tokyo, Japão, 113-8519
        • Tokyo Medical and Dental University Hospital
      • Christchurch, Nova Zelândia, 8011
        • Christchurch Hospital (Canterbury Health Laboratories)
      • Tauranga, Nova Zelândia, 3112
        • Tauranga Hospital
      • Bydgoszcz, Polônia, 85-168
        • Szpital Uniwersytecki Nr Im Dr Jana Biziela
      • Chorzów, Polônia, 41-503
        • Silesian Healthy Blood Clinic
      • Gdansk, Polônia, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Gdask, Polônia, 80-219
        • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
      • Gdynia, Polônia, 81-519
        • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
      • Krakow, Polônia, 30-727
        • Pratia McM Krakow
      • Legnica, Polônia, 59-220
        • Wojewodzki Szpital Specjalistyczny W Legnicy
      • Lodz, Polônia, 93-510
        • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Polônia, 20-090
        • Centrum Onkologii Ziemi Lubelskiej
      • Warsaw, Polônia, 02-776
        • Instytut Hematologii I Transfuzjologii W Warszawie
      • Wałbrzych, Polônia, 58-309
        • Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
      • Wroclaw, Polônia, 50-556
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Lisbon, Portugal, 1099-023
        • Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
      • Lisbon, Portugal, 1649-035
        • Chuln Hospital de Santa Maria
      • Porto, Portugal, 4099-001
        • Centro Hospitalar Universitario Porto
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
      • Abergavenny, Reino Unido, NP7 7EG
        • Aneurin Bevan University Health Board
      • Birmingham, Reino Unido, B9 5SS
        • Birmingham Heartlands Hospital
      • Dudley, Reino Unido, DY1 2HQ
        • Russells Hall Hopsital
      • Sutton, Reino Unido, SM2 5PT
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Bucharest, Romênia, 022328
        • Institutul Clinic Fundeni
      • Iași, Romênia, 700483
        • Institutul Regional de Oncologie Iasi
      • Moscow, Rússia, 142770
        • Gbuz Mmcc Kommunarka Dzm
    • Moscow
      • Moscow, Moscow, Rússia, 125284
        • Clinical Hospital, Sp Botkin
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Rússia, 191024
        • Fgu Russian Scientific Research Institute of Hematology and Transfusiology
      • Saint Petersburg, Sankt-Peterburg, Rússia, 194291
        • Leningrad Regional Clinic and Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Tainan, Taiwan, 736
        • Chi Mei Hospital Liouying
      • Taipei, Taiwan, 114
        • Tri Service General Hospital
      • Ankara, Turquia (Türkiye), 06620
        • Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
      • Ankara, Turquia (Türkiye), 6500
        • Gazi University
      • Ankara, Turquia (Türkiye), 06700
        • Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
      • Edirne, Turquia (Türkiye), 22030
        • Tr Trakya University Health Research and Application Center (Hospital)
      • Istanbul, Turquia (Türkiye), 34365
        • Vkv American Hospital
      • Mersin, Turquia (Türkiye), 33000
        • Mersin Universitesi Tip Fakultesi Hastanesi
      • Cherkasy, Ucrânia, 18009
        • Cherkasy Regional Oncology Dispensary
      • Dnipro, Ucrânia, 49102
        • Municipal Non Profit Enterprise City Clinical Hospital
      • Kiev, Ucrânia, 3022
        • National Cancer Institute
      • Lviv, Ucrânia, 79044
        • Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
      • Linz, Áustria, 4020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Salzburg, Áustria, 5020
        • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
      • Vienna, Áustria, 1090
        • Medical University Vienna Oncology

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

60 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  1. ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
  2. Histologically confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. Measurable disease by CT/MRI
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. Clinically significant cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A: zanubrutinib plus rituximab

Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

Administered as two 80 mg capsules by mouth twice a day

Outros nomes:
  • Brukinsa
  • BGB-3111

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Comparador Ativo: Arm B: bendamustine plus rituximab

Participants will receive bendamustine plus rituximab, followed by observation.

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival (PFS) determined by independent central review
Prazo: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
PFS by investigator assessment
Prazo: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years
Overall response rate (ORR)
Prazo: Up to approximately 7 years

ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

Up to approximately 7 years
Duration of response (DOR)
Prazo: Up to approximately 7 years

DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

Up to approximately 7 years
Overall survival (OS)
Prazo: Up to approximately 7 years

OS is defined as the time from randomization to the date of death due to any reason.

Up to approximately 7 years
Time to Response (TTR)
Prazo: Up to approximately 7 years

TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

Up to approximately 7 years
Rate of complete response (CR) or complete metabolic response
Prazo: Up to approximately 7 years

Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

Up to approximately 7 years
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
Prazo: Up to approximately 7 years

EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

Up to approximately 7 years
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Prazo: Up to approximately 7 years

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Up to approximately 7 years
Number of participants with adverse events and serious adverse events
Prazo: Up to approximately 7 years

Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

Up to approximately 7 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Study Director, BeOne Medicines

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de agosto de 2019

Conclusão Primária (Real)

27 de abril de 2026

Conclusão do estudo (Estimado)

30 de setembro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

27 de junho de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de junho de 2019

Primeira postagem (Real)

28 de junho de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • BGB-3111-306
  • 2019-000413-36 (Número EudraCT)
  • CTR20211594 (Identificador de registro: ChinaDrugTrials)
  • 2023-509908-15-00 (Ctis)
  • 2023 (Concessão/Contrato do NIH dos EUA)
  • 2019 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Prazo de Compartilhamento de IPD

See plan description

Critérios de acesso de compartilhamento IPD

See plan description

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .